TipRanks on MSN

Novo Nordisk’s Refixia® Study: A Closer Look at Long-term Safety and Effectiveness

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a post-marketing ...

New menopause drug to target hot flashes without hormones gets FDA approval

The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, ...

New menopause drug without hormones approved by FDA. A doctor shares what to know.

The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot ...

Potential cancer outcome differences among psoriasis biologics found

Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern ...

Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT ...